Gensight Biologics S.a annual capital expenditures (capex)
2020
2021
2022
2023
2024
2025
Gensight Biologics S.a Capital Expenditures (CapEx) Growth & History (SIGHT)
Gensight Biologics S.a's capital expenditures (capex) was €4,000 for fiscal 2025.
View full Gensight Biologics S.a company overviewGensight Biologics S.a annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €4,000 | €3,000 | +300.00% |
| 2024 | 2024-12-31 | €1,000 | −€9,000 | −90.00% |
| 2023 | 2023-12-31 | €10,000 | −€242,000 | −96.03% |
| 2022 | 2022-12-31 | €252,000 | €220,000 | +687.50% |
| 2021 | 2021-12-31 | €32,000 | €26,000 | +433.33% |
| 2020 | 2020-12-31 | €6,000 | — | — |
Gensight Biologics S.a capital expenditures (capex) trends
Over the last five fiscal years, Gensight Biologics S.a's capital expenditures (capex) decreased from €6,000 to €4,000, a change of −€2,000.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company official filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gensight Biologics S.a source filings ↗Community posts
GenSight advances LUMEVOQ manufacturing transfer to Catalent
GenSight ($SIGHT) said an engineering batch of GS010/LUMEVOQ at Catalent was produced as planned, with viral genome concentration meeting target specifications. Preparations have begun for a GMP-standard batch to supply special-access progr ...